InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.700

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$334 VIRALEZE to be launched with LloydsPharmacy in the UK 25 Mar 2021 8:23AM $2.030 $0.700 fallen by 65.52%
$334 DEP HER2-lutetium outperforms in human breast cancer model 16 Mar 2021 10:16AM $1.895 $0.700 fallen by 63.06%
$334 SPL7013 active against other pandemic coronaviruses 3 Mar 2021 9:44AM $2.100 $0.700 fallen by 66.67%
$334 Interim Report and Half-Year Financial Results 25 Feb 2021 9:48AM $2.140 $0.700 fallen by 67.29%
$334 VIRALEZE antiviral nasal spray registered in Europe 23 Feb 2021 9:19AM $2.200 $0.700 fallen by 68.18%
$334 Starpharma signs DEP ADC Research Agreement with MSD 12 Feb 2021 9:45AM $2.040 $0.700 fallen by 65.69%
$334 AZD0466 clinical DEP program global expansion 9 Feb 2021 8:46AM $1.950 $0.700 fallen by 64.10%
$334 Change in substantial holding 3 Feb 2021 8:15AM $1.595 $0.700 fallen by 56.11%
$334 Quarterly Cashflow and Activities Report 29 Jan 2021 10:03AM $1.505 $0.700 fallen by 53.49%
$334 Appendix 2A 27 Jan 2021 2:40PM $1.498 $0.700 fallen by 53.26%
$334 Change in substantial holding 18 Jan 2021 8:20AM $1.500 $0.700 fallen by 53.33%
$334 Change in substantial holding 18 Jan 2021 8:20AM $1.500 $0.700 fallen by 53.33%
$334 Change in substantial holding 24 Dec 2020 8:21AM $1.550 $0.700 fallen by 54.84%
$334 VIRALEZE COVID-19 nasal spray study to commence in January 22 Dec 2020 11:39AM $1.490 $0.700 fallen by 53.02%
$334 Change in substantial holding 22 Dec 2020 8:17AM $1.535 $0.700 fallen by 54.40%
$334 VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21 10 Dec 2020 10:19AM $1.310 $0.700 fallen by 46.56%
$334 Change in Director's Interest Notice - J Fairley 24 Nov 2020 2:27PM $1.358 $0.700 fallen by 48.43%
$334 Appendix 3G 24 Nov 2020 2:24PM $1.358 $0.700 fallen by 48.43%
$334 Retirement of non-executive director Richard Hazleton 20 Nov 2020 2:18PM $1.385 $0.700 fallen by 49.46%
$334 2020 AGM Results 20 Nov 2020 2:10PM $1.385 $0.700 fallen by 49.46%
$334 AGM Chairman address and CEO presentation 20 Nov 2020 10:12AM $1.310 $0.700 fallen by 46.56%
$334 SPL7013 shows potent antiviral activity in RSV 19 Nov 2020 9:39AM $1.315 $0.700 fallen by 46.77%
$334 Appendix 3G 13 Nov 2020 1:03PM $1.275 $0.700 fallen by 45.10%
$334 Change in Director's Interest Notice - R Thomas 4 Nov 2020 10:50AM $1.355 $0.700 fallen by 48.34%
$334 Change in Director's Interest Notice - J Fairley 4 Nov 2020 10:44AM $1.340 $0.700 fallen by 47.76%

326 - 350 of 875 results

Page 14 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.